// App-Quantinova.ai

D78 : Impact of Immunosuppression Adherence on De Novo Donor-Specific Antibody Formation in Renal Transplant Recipients in Canada: A Modeling Analysis.

Researchers

Presenter

  • J. Howell

Principal Investigators

  • R. Pollock

  • J. Schwartz

Medical Centers

  • Astellas Pharma Global Development, Markham, ON, Canada

  • Ossian Health Economics and Communications GmbH, Basel, Switzerland

  • Astellas Pharma Global Development, Inc., Northbrook, IL

Locations

  • Canada

  • Switzerland

  • United States

Companies

  • Astellas Pharma US,

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • N/A

Biomarkers

  • Progesterone receptor

Drug/Treatment

  • Cyclosporine eent

  • Tacrolimus

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved